Jennifer E Naylor1, Kevin B Freeman2, Bruce E Blough3, William L Woolverton2, Sally L Huskinson2. 1. Division of Neurobiology and Behavior Research, Department of Psychiatry and Human Behavior, The University of Mississippi Medical Center, Jackson, MS 39216, United States. Electronic address: jnaylor@umc.edu. 2. Division of Neurobiology and Behavior Research, Department of Psychiatry and Human Behavior, The University of Mississippi Medical Center, Jackson, MS 39216, United States. 3. Center for Drug Discovery, Research Triangle Institute, Research Triangle Park, NC 27709, United States.
Abstract
BACKGROUND: Synthetic cathinones are beta-ketophenethylamine analogs manufactured to avoid legal restrictions placed on illicit stimulants like methamphetamine. Regulating these "emerging" designer drugs require scientific evidence of abuse potential. METHODS: The present study evaluated the discriminative-stimulus effects of three synthetic cathinones, recently identified in commercial and confiscated products, in male Sprague-Dawley rats trained to discriminate methamphetamine (1.0 mg/kg) from saline under a fixed-ratio (FR) 20 schedule of food delivery. Three synthetic cathinones, 4-methyl-N-ethylcathinone (4-MEC; 1.0-8.0 mg/kg), 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP; 4.0-16.0 mg/kg), and alpha-pyrrolidinopentiophenone (alpha-PVP; 0.25-2.0 mg/kg) were tested for their ability to substitute for methamphetamine. RESULTS: Full substitution for the training dose of methamphetamine occurred at the highest doses for both 4-MePPP and alpha-PVP, and 4-MEC did not substitute at any dose tested. CONCLUSIONS: The present findings show that two synthetic cathinones, 4-MePPP and alpha-PVP, produced subjective effects similar to those of methamphetamine. The synthetic cathinone, 4-MEC, did not produce subjective effects similar to those of methamphetamine with the parameters used in the current experiment. Based on findings here and by others, these three compounds warrant further tests of abuse potential.
BACKGROUND: Synthetic cathinones are beta-ketophenethylamine analogs manufactured to avoid legal restrictions placed on illicit stimulants like methamphetamine. Regulating these "emerging" designer drugs require scientific evidence of abuse potential. METHODS: The present study evaluated the discriminative-stimulus effects of three synthetic cathinones, recently identified in commercial and confiscated products, in male Sprague-Dawley rats trained to discriminate methamphetamine (1.0 mg/kg) from saline under a fixed-ratio (FR) 20 schedule of food delivery. Three synthetic cathinones, 4-methyl-N-ethylcathinone (4-MEC; 1.0-8.0 mg/kg), 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP; 4.0-16.0 mg/kg), and alpha-pyrrolidinopentiophenone (alpha-PVP; 0.25-2.0 mg/kg) were tested for their ability to substitute for methamphetamine. RESULTS: Full substitution for the training dose of methamphetamine occurred at the highest doses for both 4-MePPP and alpha-PVP, and 4-MEC did not substitute at any dose tested. CONCLUSIONS: The present findings show that two synthetic cathinones, 4-MePPP and alpha-PVP, produced subjective effects similar to those of methamphetamine. The synthetic cathinone, 4-MEC, did not produce subjective effects similar to those of methamphetamine with the parameters used in the current experiment. Based on findings here and by others, these three compounds warrant further tests of abuse potential.
Authors: Gregory C Hadlock; Katy M Webb; Lisa M McFadden; Pei Wen Chu; Jonathan D Ellis; Scott C Allen; David M Andrenyak; Paula L Vieira-Brock; Christopher L German; Kevin M Conrad; Amanda J Hoonakker; James W Gibb; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein Journal: J Pharmacol Exp Ther Date: 2011-08-02 Impact factor: 4.030
Authors: Kurt J Varner; Kyle Daigle; Peter F Weed; Peter B Lewis; Sarah E Mahne; Ananthakrishnan Sankaranarayanan; Peter J Winsauer Journal: Psychopharmacology (Berl) Date: 2012-09-13 Impact factor: 4.530
Authors: Lucas R Watterson; Peter R Kufahl; Natali E Nemirovsky; Kaveish Sewalia; Megan Grabenauer; Brian F Thomas; Julie A Marusich; Scott Wegner; M Foster Olive Journal: Addict Biol Date: 2012-07-11 Impact factor: 4.280
Authors: Craig P Motbey; Kelly J Clemens; Nadine Apetz; Adam R Winstock; John Ramsey; Kong M Li; Naomi Wyatt; Paul D Callaghan; Michael T Bowen; Jennifer L Cornish; Iain S McGregor Journal: J Psychopharmacol Date: 2013-06-05 Impact factor: 4.153
Authors: Lucas R Watterson; Lauren Hood; Kaveish Sewalia; Seven E Tomek; Stephanie Yahn; Craig Trevor Johnson; Scott Wegner; Bruce E Blough; Julie A Marusich; M Foster Olive Journal: J Addict Res Ther Date: 2012-12-01
Authors: S L Huskinson; J E Naylor; E A Townsend; J K Rowlett; B E Blough; K B Freeman Journal: Psychopharmacology (Berl) Date: 2016-11-28 Impact factor: 4.530
Authors: Brenda M Gannon; Kayla I Galindo; Melson P Mesmin; Agnieszka Sulima; Kenner C Rice; Gregory T Collins Journal: Neuropharmacology Date: 2017-08-12 Impact factor: 5.250
Authors: Amy J Eshleman; Katherine M Wolfrum; John F Reed; Sunyoung O Kim; Tracy Swanson; Robert A Johnson; Aaron Janowsky Journal: J Pharmacol Exp Ther Date: 2016-10-31 Impact factor: 4.030
Authors: Steven J Simmons; Jonna M Leyrer-Jackson; Chicora F Oliver; Callum Hicks; John W Muschamp; Scott M Rawls; M Foster Olive Journal: ACS Chem Neurosci Date: 2018-05-11 Impact factor: 4.418